Effects of device and formulation on in vitro performance of dry powder inhalers

AAPS Journal

Volumn 14, Issue 3, 2012, Pages 400-409

  Adams, Wallace P ^a   Lee, Sau L ^b   Plourde, Robert ^c   Lionberger, Robert A ^b   Bertha, Craig M ^b   Doub, William H ^b   Bovet, Jean Marc ^d   Hickey, Anthony J ^d,e  

^a CDER/OPS/Office of Generic Drugs ^*

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^c CATALENT PHARMA SOLUTIONS   (United States)

^d Research Triangle Institute   (United States)

^e RTI INTERNATIONAL   (United States)

Author keywords

device modifications; dry powder inhaler; formulation; generic; in vitro performance

Indexed keywords

ASTHALIN ROTACAP; LACTOSE; SALBUTAMOL SULFATE; UNCLASSIFIED DRUG; VENTOLIN ROTACAP;

AIRFLOW; ARTICLE; CONTROLLED STUDY; DISPERSION; DRUG FORMULATION; EQUIPMENT DESIGN; IN VITRO STUDY; PARTICLE SIZE; PERFORMANCE MEASUREMENT SYSTEM; POWDER INHALER; SENSITIVITY ANALYSIS; SOLID STATE;

AEROSOLS; CHEMISTRY, PHARMACEUTICAL; NEBULIZERS AND VAPORIZERS; POWDERS;

EID: 84862767061     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-012-9352-7     Document Type: Article

References (29)

1. US Environmental Protection Agency (EPA) 1993 Protection of stratospheric ozone; labeling Fed Regist 58 8136 69
2. US Department of Health and Human Services (DHHS). Food and Drug Administration (FDA) 1999 Use of ozone-depleting substances; essential use determinations Fed Regist 64 47719 41
3. SL Lee WP Adams BV Li DP Conner BA Chowdhury LX Yu 2009 in vitro considerations to support bioequivalence of locally acting drugs in dry powder inhalers for lung diseases AAPS J 11 414 23 19495991 10.1208/s12248-009-9121-4 1:CAS:528:DC%2BD1MXhsFGmtbfJ
4. KA Fults IF Miller AJ Hickey 1997 Effect of particle morphology on emitted dose of fatty acid-treated disodium cromoglycate powder aerosols Pharm Dev Technol 2 67 79 9552432 10.3109/10837459709022610 1:CAS:528: DyaK2sXhsl2ktbg%3D
5. CA Dunbar AJ Hickey P Holzner 1998 Dispersion and characterization of pharmaceutical dry powder aerosols Kona. 16 7 45 1:CAS:528:DC%2BD3MXjtlKjtLg%3D
6. Gonda I. Targeting by deposition. In: Hickey AJ, editor. Pharmaceutical inhalation aerosol technology. 2nd ed. New York: Marcel Dekker; 2004. p. 65-88.
7. MJ Telko AJ Hickey 2005 Dry powder inhaler formulation Respir Care. 50 1209 27 16122404
8. MJ Donovan HD Smyth 2010 Influence of size and surface roughness of large lactose carrier particles in dry powder inhaler formulations Int J Pharm 402 1 9 20816928 10.1016/j.ijpharm.2010.08.045 1:CAS:528:DC%2BC3cXhsVWhurfK
9. E Guenette A Barrett D Kraus R Brody L Harding G Magee 2009 Understanding the effect of lactose particle size on the properties of DPI formulations using experimental design Int J Pharm 380 80 8 19596428 10.1016/j.ijpharm.2009.07.002 1:CAS:528:DC%2BD1MXhtV2hsbvO
10. USP Advisory Panel on Aerosols 1994 Recommendations of the USP advisory panel on aerosols on the USP general chapters on aerosols <601> and uniformity of dosage units <905> Pharm Forum 20 7477 7503
11. HW Frijlink AH De Boer 2004 Dry powder inhalers for pulmonary drug delivery Expert Opin Drug Deliv. 1 67 86 16296721 10.1517/17425247.1.1.67 1:STN:280:DC%2BD2MnhvV2hug%3D%3D
12. AR Clark AM Hollingworth 1993 The relationship between powder inhaler resistance and peak inspiratory conditions in healthy volunteers-implications for in vitro testing J Aerosol Med. 6 99 110 10146277 10.1089/jam.1993.6.99 1:STN:280:DyaK2cbgsFGhsQ%3D%3D
13. GP Martin XM Zeng SK Tee A Abu Ghoush C Marriott 1999 Effects of particle size and adding sequence of fine lactose on the deposition of salbutamol sulphate from a dry powder formulation Int J Pharm 182 133 44 10341303 10.1016/S0378-5173(99)00021-6
14. Menzeleev R, Bovet J-M, Hickey AJ. Unit dose level particle size distribution characterization of inhalation products: a new analytical approach using LC-MSD as a platform. In: Dalby RN, Byron PR, Peart J, Suman JD, Farr SL, editors. Respiratory drug delivery IX. River Grove: Davis Healthcare International Publishing; 2004. p. 453-6.
15. <601> Aerosols. Metered-dose inhalers and dry powder inhalers, data analysis. Rockville: U.S. Pharmacopeia 31/National Formulary 26, United States Pharmacopeial Convention; 2008.
16. Berg RL, Svensson JO, Asking L. MMAD based on dose to impactor rather than on delivered dose. In: Dalby RN, Byron PR, Peart J, Farr SL, editors. Respiratory drug delivery VIII. Godalming: Davis Horwood International; 2002. p. 339-42.
17. <601> Aerosols. Metered-dose inhalers and dry powder inhalers, sampling the delivered dose from dry powder inhalers. Rockville: U.S. Pharmacopeia 31/National Formulary 26, United States Pharmacopeial Convention; 2008.
18. I Saleem H Smyth M Telko 2008 Prediction of dry powder inhaler formulation performance from surface energetics and blending dynamics Drug Dev Ind Pharm. 34 1002 10 18686090 10.1080/03639040802154905 1:CAS:528: DC%2BD1cXhtFais77K
19. M Hindle PR Byron 1995 Dose emissions from marketed dry powder inhalers Int J Pharm 116 169 77 10.1016/0378-5173(94)00287-F 1:CAS:528:DyaK2MXjs1Gisrw%3D
20. PR Byron 2004 Drug delivery devices: issues in drug development Proc Am Thorac Soc 1 321 8 16113453 10.1513/pats.200403-023MS 1:CAS:528: DC%2BD28XhsFGjsL8%3D
21. NYK Chew HK Chan 2001 in vitro aerosol performance and dose uniformity between the Foradile (R) Aerolizer (R) and the Oxis (R) Turbuhaler (R) J Aerosol Med. 14 495 501 11791690 10.1089/08942680152744703 1:STN:280: DC%2BD38%2Fms1Wjsg%3D%3D
22. RH Bridson PT Robbins Y Chen D Westerman CR Gillham TC Roche, et al. 2007 The effects of high shear blending on alpha-lactose monohydrate Int J Pharm 339 84 90 17398047 10.1016/j.ijpharm.2007.02.022 1:CAS:528:DC%2BD2sXntFejsbo%3D
23. MD Jones JC Hooton ML Dawson AR Ferrie R Price 2008 An investigation into the dispersion mechanisms of ternary dry powder inhaler formulations by the quantification of interparticulate forces Pharm Res 25 337 48 17952568 10.1007/s11095-007-9467-1 1:CAS:528:DC%2BD1cXitVejtrs%3D
24. J Shur H Harris MD Jones JS Kaerger R Price 2008 The role of fines in the modification of the fluidization and dispersion mechanism within dry powder inhaler formulations Pharm Res 25 1931 40 10.1007/s11095-008-9538-y
25. MD Louey M Van Oort AJ Hickey 2004 Aerosol dispersion of respirable particles in narrow size distributions produced by jet-milling and spray-drying techniques Pharm Res 21 1200 6 15290860 10.1023/B:PHAM.0000033007.27278.60 1:CAS:528:DC%2BD2cXltF2gtr4%3D
26. MS Coates HK Chan DF Fletcher JA Raper 2005 Influence of air flow on the performance of a dry powder inhaler using computational and experimental analyses Pharm Res 22 1445 53 16132356 10.1007/s11095-005-6155-x 1:CAS:528:DC%2BD2MXptVWlurg%3D
27. MS Coates HK Chan DF Fletcher JA Raper 2006 Effect of design on the performance of a dry powder inhaler using computational fluid dynamics. Part 2: air inlet size J Pharm Sci 95 1382 92 16625656 10.1002/jps.20603 1:CAS:528:DC%2BD28XlsFWlsbk%3D
28. MS Coates DF Fletcher HK Chan JA Raper 2004 Effect of design on the performance of a dry powder inhaler using computational fluid dynamics. Part 1: grid structure and mouthpiece length J Pharm Sci 93 2863 76 15389665 10.1002/jps.20201 1:CAS:528:DC%2BD2cXpvV2itrs%3D
29. MS Coates DF Fletcher HK Chan JA Raper 2005 The role of capsule on the performance of a dry powder inhaler using computational and experimental analyses Pharm Res 22 923 32 15948036 10.1007/s11095-005-4587-y 1:CAS:528:DC%2BD2MXltVKnur8%3D